Streetbeat News

Revenues

NTRA

Natera, Inc. (NASDAQ:NTRA) has expressed support for the new KDIGO guideline, which recommends genetic testing for most chronic kidney disease (CKD) patients to identify the disease's cause. This guideline aligns with Natera's Renasight test, potentially leading to broader adoption. The guideline's endorsement is based on the RenaCARE study, which showed the diagnostic utility of Renasight in CKD patients. Over 55% of U.S. nephrologists have ordered the Renasight test, indicating significant clinical acceptance.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:53 pm

ABVC

ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its fiscal year 2024 Q1 business update, highlighting a licensing deal with AiBtl BioPharma Inc. for CNS drugs, regaining Nasdaq compliance, strategic investments in real estate for healthcare development, and various financial transactions including securities purchase agreements with Lind Global Fund II, LP. The company reported a decrease in revenues and operating expenses, a net loss reduction, and progress in R&D including patents, FDA approvals, and a licensing agreement with Xinnovation Therapeutics Co., Ltd for the Chinese market.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:35 pm

CSIQ

Canadian Solar Inc (NASDAQ:CSIQ) reported a 14% year-on-year decline in Q4 fiscal 2023 revenue to $1.70 billion, slightly above consensus estimates. Despite a decrease in module average selling price and lower project sales, total module shipments increased by 26% Y/Y to 8.2 GW. The company experienced a decrease in EPS to $(0.02), down from $1.11 in Q4 2022. Gross profit and margin also declined due to lower ASPs and an inventory write-down. Operating cash flow decreased to $190 million from $395.4 million last year. CSIQ provided a conservative Q1 outlook with expected revenue of $1.20 billion to $1.40 billion, below consensus estimates, and anticipates a gross margin of 17% - 19%. For fiscal 2024, revenue is expected to be between $8.50 billion and $9.50 billion, with total module shipments of 42 GW - 47 GW and battery energy storage shipments of 6.0 GWh - 6.5 GWh. CSIQ shares rose 1.15% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

March 14, 2024 | 1:34 pm

ENFN

Spruce Point Capital Management issued a short report on Enfusion (ENFN), estimating a 40% to 60% downside risk due to concerns over financial restatement risk, executive turnover, and industry challenges. The report criticizes Enfusion's quality as a SaaS provider and highlights potential revenue misstatement issues.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:32 pm

AMC

DIS

LYV

The Walt Disney Company (NYSE:DIS) acquired streaming rights for Taylor Swift's concert film, 'The Eras Tour (Taylor's Version)', set to release on Disney+ on March 14. The film, previously shown in theaters through a partnership with AMC Entertainment Holdings (NYSE:AMC), grossed over $261.7 million worldwide. Live Nation Entertainment (NYSE:LYV) also benefited from the demand for Swift's concerts. Disney's exclusive streaming rights could attract more subscribers to Disney+, potentially boosting its stock in the short term.

Portfolio Pulse from Chris Katje

March 14, 2024 | 1:19 pm

GMGI

Golden Matrix Group (NASDAQ:GMGI) reported a 9.89% increase in Q1 sales to $11.84M from $10.78M YoY.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:18 pm

BTCUSD

ETHUSD

SPY

Cryptocurrencies like Bitcoin, Ethereum, and Dogecoin show mixed trading signals, with Ethereum completing the 'Dencun' upgrade. Dogecoin's value may rise as Tesla considers accepting it for payments. Hacken's market cap reaches $57M after unveiling a tokenized share offering. Bitcoin critic Peter Schiff expresses regret over not investing in Bitcoin earlier. Crypto miners see record profits amid a Bitcoin rally. US markets see mixed movements with Hello Group and others moving lower. Political and global events include potential lawsuits, defense decisions, and tech partnerships. Electric vehicle market updates include Tesla's plans and competition from Polestar. Consumer, communication, healthcare, general news, space, and energy sectors also see significant updates.

Portfolio Pulse from Akanksha Bakshi

March 14, 2024 | 1:13 pm

BBW

Build-A-Bear Workshop's shares increased following the announcement of Q4 earnings per share (EPS) that exceeded expectations, despite missing revenue forecasts. The company also projected revenue growth for FY24 in the low-to-mid-single-digit percentage range.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:11 pm

GRI

GRI Bio, Inc. (NASDAQ:GRI) announced the Canadian Intellectual Property Office's notice of allowance for a patent covering NKT cell modulators for treating inflammatory, fibrotic, and autoimmune diseases. This development is part of GRI Bio's efforts to protect its innovative pipeline globally. The company is advancing its lead program, GRI-0621, for treating Idiopathic Pulmonary Fibrosis, with interim Phase 2a data expected in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:02 pm

LULU

Analyst ratings for Lululemon Athletica (NASDAQ:LULU) show a mix of bullish to bearish sentiments. Recent updates include maintained and raised ratings with an average 12-month price target of $520.14, reflecting a slight increase from the previous target. Lululemon's financial performance is strong, with significant revenue growth, high net margin, and efficient asset management. The company's market position is solid, indicated by its substantial market capitalization and above-average financial metrics.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 1:01 pm